Home
NICE Guidance
Published Guidance

Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer

Technology appraisal guidance [TA107] Published: 23 August 2006

Guidance

This guideline has been updated and replaced by NICE guideline NG101.